Notes
2016 US dollars
Reference
Pelligra CG, et al. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. Clinical Therapeutics : 26 Sep 2017. Available from: URL: http://doi.org/10.1016/j.clinthera.2017.08.010
Rights and permissions
About this article
Cite this article
Pomalidomide cost effective for multiple myeloma. PharmacoEcon Outcomes News 789, 26 (2017). https://doi.org/10.1007/s40274-017-4433-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4433-6